Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2300 (LINC02300) is classified as a long intergenic non-coding RNA (lincRNA)—a subclass of long non-coding RNAs (lncRNAs) that do not overlap with protein-coding genes and are typically longer than 200 nucleotides[3][1][5]. lincRNAs are known to play diverse regulatory roles within the cell, including fine-tuning gene expression, modulating chromatin architecture, sequestering specific proteins or RNAs, and sometimes acting as enhancer RNAs, although functional annotation for most lincRNAs (including LINC02300) remains incomplete[5][7][8][9]. There is no established evidence that LINC02300 encodes a protein, acts as a druggable therapeutic target, or is directly implicated in particular human diseases[1][3]. As is typical for most annotated lincRNAs, LINC02300 may contribute to various gene regulatory networks, but its specific biological function is not yet documented in the scientific literature[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2300 (LINC02300).